Loading companies…
ST
Sling Therapeutics, Inc.
United States · Biotech
A clinical-stage biotechnology company developing an oral drug candidate for thyroid eye disease.
An oral approach under clinical evaluation
Sling's lead candidate, linsitinib, inhibits the insulin-like growth factor 1 receptor, a target involved in thyroid eye disease. The company is evaluating the small molecule as an oral treatment option.
In September 2026, Sling announced that the first patients had been dosed in its global Phase 3 ORBIT trial. The programme remains in clinical development; the company is based in Ann Arbor, Michigan.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series C | $123M | Forbion — LeadSectoral Asset Management — ParticipantTPG Life Sciences Innovations — Participant |
Investors
ForbionLed Series CSectoral Asset ManagementJoined Series CTPG Life Sciences InnovationsJoined Series CCoverage
Sep 16, 2026Sling Therapeutics, Inc. · Series CSimilar companies
AnaCardioAnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure.€62.5M · Series B
AventixAventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results.€1.2M · Pre-seed
ATAptadir TherapeuticsRNA therapeutics designed to restore expression of silenced genes€40M · Seed